Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.

Osamah M AlfayezOmar A AlmohammedOmar S AlkheziAbdulaali R AlmutairiMajed S Al Yami

Published in: Cardiovascular diabetology (2020)

The GLP1RAs have shown significant benefits in terms of CV safety. The indirect comparison and ranking probability results have shown that one weekly semaglutide and oral semaglutide seems to be the preferred option in patients with T2DM and established or at high risk of CVD. This result can aid health care providers, pharmacy and therapeutics committees in hospitals, and insurance companies when deciding which GLP1RA to start or add to their formulary.

Keyphrases

healthcare
systematic review
rheumatoid arthritis
cardiovascular events
meta analyses
cardiovascular disease
risk factors
metabolic syndrome
coronary artery disease
systemic lupus erythematosus
social media
health information
glycemic control
long term care